bluebird bio has announced the filing by 2seventy bio of an updated Registration Statement with the US Securities and Exchange Commission (SEC).
This reflects bluebird bio’s plans for a spin-off of its oncology programmes and portfolio into 2seventy bio. The spin-off is on track to be completed by early November 2021.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,